H
H. Einsele
Researcher at University of Würzburg
Publications - 15
Citations - 2449
H. Einsele is an academic researcher from University of Würzburg. The author has contributed to research in topics: Transplantation & Imatinib mesylate. The author has an hindex of 10, co-authored 15 publications receiving 2205 citations.
Papers
More filters
Journal ArticleDOI
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
Eva Hoster,Martin Dreyling,Wolfram Klapper,Christian Gisselbrecht,Achiel Van Hoof,Hanneke C. Kluin-Nelemans,Michael Pfreundschuh,Marcel Reiser,Bernd Metzner,H. Einsele,Norma Peter,Wolfram Jung,Bernhard Wörmann,Wolf-Dieter Ludwig,Ulrich Dührsen,Hartmut Eimermacher,Hannes Wandt,Joerg Hasford,Wolfgang Hiddemann,Michael Unterhalt +19 more
TL;DR: The MIPI as discussed by the authors is the first prognostic index particularly suited for mantle cell lymphoma patients and may serve as an important tool to facilitate risk-adapted treatment decisions in patients with advanced stage MCL.
Journal ArticleDOI
Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma
Annina Herrmann,Eva Hoster,Thomas Zwingers,Günter Brittinger,Marianne Engelhard,Meusers P,Marcel Reiser,Roswitha Forstpointner,Bernd Metzner,Norma Peter,Bernhard Wörmann,Lorenz Trümper,Michael Pfreundschuh,H. Einsele,Wolfgang Hiddemann,Michael Unterhalt,Martin Dreyling +16 more
TL;DR: Median overall survival of patients with advanced nonblastoid MCL almost doubled during the past 30 years, questioning the validity of historical comparisons which had been frequently applied in previous trials.
Journal ArticleDOI
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).
Benjamin Hanfstein,Martin C. Müller,Rüdiger Hehlmann,Philipp Erben,Michael Lauseker,Alice Fabarius,Susanne Schnittger,Claudia Haferlach,Gudrun Göhring,Ulrike Proetel,Hans-Jochem Kolb,Stefan W. Krause,Wolf-K. Hofmann,J. Schubert,H. Einsele,Jolanta Dengler,Mathias Hänel,C. Falge,Lothar Kanz,Andreas Neubauer,Michael Kneba,Frank Stegelmann,Michael Pfreundschuh,Cornelius F. Waller,Susan Branford,Susan Branford,Timothy P. Hughes,Karsten Spiekermann,Gabriela M. Baerlocher,Markus Pfirrmann,Joerg Hasford,Susanne Saußele,Andreas Hochhaus +32 more
TL;DR: Treatment optimization is recommended for pts missing these landmarks and early prediction of prognosis on imatinib is desirable to assure favorable survival or otherwise consider the use of a second-generation tyrosine kinase inhibitor (TKI).
Journal ArticleDOI
Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV
Rüdiger Hehlmann,Martin C. Müller,Michael Lauseker,Benjamin Hanfstein,Alice Fabarius,Annette Schreiber,Ulrike Proetel,Nadine Pletsch,Markus Pfirrmann,Claudia Haferlach,Susanne Schnittger,H. Einsele,Jolanta Dengler,Christiane Falge,Lothar Kanz,Andreas Neubauer,Michael Kneba,Frank Stegelmann,Michael Pfreundschuh,Cornelius F. Waller,Karsten Spiekermann,Gabriela M. Baerlocher,Gerhard Ehninger,Dominik Heim,Hermann Heimpel,Christoph Nerl,Stefan W. Krause,Dieter K. Hossfeld,Hans-Jochem Kolb,Joerg Hasford,Susanne Saußele,Andreas Hochhaus +31 more
TL;DR: MR(4.5) is a new molecular predictor of long-term outcome, is reached by a majority of patients treated with imatinib, and is achieved more quickly with optimized high-dose imatin ib, which may provide an improved therapeutic basis for treatment discontinuation in CML.
Journal ArticleDOI
Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV
Alice Fabarius,Armin Leitner,Andreas Hochhaus,Martin C. Müller,Benjamin Hanfstein,Claudia Haferlach,Gudrun Göhring,Brigitte Schlegelberger,Martine Jotterand,Andreas Reiter,Susanne Jung-Munkwitz,Ulrike Proetel,Juliana Schwaab,Wolf-Karsten Hofmann,J. Schubert,H. Einsele,Anthony D. Ho,Christiane Falge,Lothar Kanz,Andreas Neubauer,Michael Kneba,Frank Stegelmann,Michael Pfreundschuh,Cornelius F. Waller,Karsten Spiekermann,Gabriela M. Baerlocher,Michael Lauseker,Markus Pfirrmann,Joerg Hasford,Susanne Saussele,Rüdiger Hehlmann +30 more
TL;DR: It is concluded that major-route ACAs at diagnosis are associated with a negative impact on survival and signify progression to the accelerated phase and blast crisis.